ABSTRACT
We analyzed regulation of the prosurvival Bcl-2 homologue A1, following T-cell receptor (TCR) or cytokine receptor engagement. Activation of CD4(+) or CD8(+) T cells by antigenic peptides induced an early but transient IL-2-independent expression of A1 and Bcl-xl mRNA and proteins, whereas expression of Bcl-2 was delayed and required IL-2. Cytokines such as IL-2, IL-4, IL-7 or IL-15 prevented apoptosis of activated T cells that effect being associated with the maintenance of Bcl-2, but not of A1 expression. However, restimulation of activated or posteffector T cells with antigenic peptide strongly upregulated A1 mRNA and maintained A1 protein expression. IL-4, IL-7 or IL-15 also prevented cell death of naive T cells. In those cells, cytokines upregulated Bcl-2, but not A1 expression. Therefore, in naive, activated and posteffector T cells, expression of A1 is dependent on TCR but not on cytokine receptor engagement, indicating that A1 is differently regulated from Bcl-xl and Bcl-2.
Subject(s)
Proto-Oncogene Proteins c-bcl-2/biosynthesis , Receptors, Antigen, T-Cell/immunology , T-Lymphocytes/immunology , Animals , Antigens/immunology , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , Cells, Cultured , Cytokines/pharmacology , Gene Expression , Lymphocyte Activation , Mice , Mice, Transgenic , Minor Histocompatibility Antigens , Peptides/immunology , Protein Isoforms/biosynthesis , Protein Isoforms/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , RNA, Messenger/metabolism , Receptors, Antigen, T-Cell/genetics , Receptors, Cytokine/metabolismSubject(s)
Immunosuppressive Agents/pharmacology , Interferon-gamma/biosynthesis , Lymphocyte Activation/drug effects , Mycophenolic Acid/pharmacology , T-Lymphocytes/immunology , Animals , Antilymphocyte Serum/pharmacology , Cells, Cultured , Humans , Interferon-gamma/blood , Interleukin-2/biosynthesis , Mice , Mice, Inbred BALB C , Muromonab-CD3/pharmacology , Mycophenolic Acid/analogs & derivatives , Phytohemagglutinins , T-Lymphocytes/drug effects , Tumor Necrosis Factor-alpha/metabolismSubject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Arthritis, Rheumatoid/drug therapy , Immunosuppressive Agents/pharmacology , Methotrexate/pharmacology , Purine Nucleotides/biosynthesis , Animals , Anti-Inflammatory Agents, Non-Steroidal/metabolism , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Apoptosis/drug effects , Apoptosis/physiology , Humans , Immunosuppressive Agents/metabolism , Immunosuppressive Agents/therapeutic use , Methotrexate/metabolism , Methotrexate/therapeutic useABSTRACT
The anthracyclines daunorubicin and doxorubicin were shown to induce apoptosis of hematopoietic cell lines. Here we report that they induce apoptosis of both nonactivated and phytohemagglutinin-activated human peripheral blood lymphocytes. Apoptosis demonstrated by surface expression of phosphatidylserine and typical nuclear alterations reached a maximum after 48 h of incubation with these agents. In contrast to topoisomerase inhibitors (etoposide and camptothecin) and antimetabolites (methotrexate and 5-fluorouracil) that induced apoptosis of activated cells only, daunorubicin and doxorubicin triggered apoptosis of cells in the G0-G1 phases of the cell cycle. In agreement with in vitro data, a single i.p. injection of daunorubicin or doxorubicin in BALB/c mice induced T- and B-cell depletion in spleen, lymph nodes, and to a lesser extent in the thymus. Soluble Fas-Fc, CD95 antagonistic antibodies, as well as the p55 tumor necrosis factor receptor-immunoglobulin fusion protein, did not inhibit drug-induced apoptosis. The level of reactive oxygen species was significantly increased in the presence of daunorubicin or doxorubicin only in nonactivated lymphocytes. However, antioxidants such as N-acetyl-L-cysteine or glutathione did not prevent apoptosis. Activation of caspase-3 after daunorubicin or doxorubicin treatment of either nonactivated or activated lymphocytes was demonstrated by the cleavage of poly(ADP-ribose) polymerase, which was, as apoptosis, inhibited by the peptide benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. Finally, daunorubicin and doxorubicin induced a rapid production of ceramides. These data indicate that anthracyclines may induce major peripheral T-cell deletion, a property not shared by many cytotoxic agents.
Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , B-Lymphocytes/drug effects , Cell Cycle/drug effects , Daunorubicin/pharmacology , Doxorubicin/pharmacology , Lymphocyte Depletion , Lymphocytes/drug effects , T-Lymphocytes/drug effects , Animals , B-Lymphocytes/cytology , Camptothecin/pharmacology , Cells, Cultured , Etoposide/pharmacology , Fluorouracil/pharmacology , G1 Phase , Humans , Lymph Nodes/immunology , Lymphocytes/cytology , Methotrexate/pharmacology , Mice , Mice, Inbred BALB C , Resting Phase, Cell Cycle , Spleen/immunology , T-Lymphocytes/cytology , Thymus Gland/immunologyABSTRACT
The effect of etoposide and camptothecin, two topoisomerase inhibitors directed against topoisomerases II and I, respectively, was evaluated on human peripheral blood lymphocytes. Etoposide and camptothecin induced apoptosis of mitogen-activated but not resting CD4+ and CD8+ T lymphocytes. Cell sensitivity to these agents required G1 to S-phase transition of the cell cycle. Conversely, daunorubicin, an intercalating agent and topoisomerase II inhibitor, induced apoptosis of both resting and activated lymphocytes. Although etoposide and camptothecin induced CD95-ligand mRNA expression, drug-induced apoptosis of activated human lymphocytes was not inhibited by CD95 antagonists. Drug-induced cell death was also not inhibited by p55 TNFR-Ig fusion protein. Activation of the caspases cascade was suggested by the partial inhibitory effect of the tripeptide zVAD-fmk and documented by activation of caspase 3. Finally etoposide and camptothecin induced a rapid production of ceramide in activated but not resting peripheral blood lymphocytes, suggesting that ceramide might initiate the signaling apoptotic cascade in sensitive cells.
Subject(s)
Apoptosis/drug effects , Camptothecin/pharmacology , DNA Topoisomerases, Type I/metabolism , Enzyme Inhibitors/pharmacology , Etoposide/pharmacology , Lymphocytes/pathology , Nucleic Acid Synthesis Inhibitors/pharmacology , Cells, Cultured , Humans , Lymphocyte Activation , Signal Transduction/drug effects , Topoisomerase I Inhibitors , fas ReceptorSubject(s)
Antilymphocyte Serum/therapeutic use , Immunosuppressive Agents/therapeutic use , Lymphocyte Depletion , Animals , Antibody Formation , Blood Platelets/immunology , Drug Monitoring , Erythrocytes/immunology , Humans , Lymphocytes/immunology , Models, Immunological , Monocytes/immunology , Neutrophils/immunology , RabbitsABSTRACT
We recently demonstrated that the engagement of HLA class I alpha1 domain induced Fas-independent apoptosis in human T and B lymphocytes. We analyzed the signaling pathway involved in HLA class I-mediated apoptosis in comparison with Fas (APO-1, CD95)-dependent apoptosis. The mouse mAb90 or the rat YTH862 monoclonal antibodies which bind the human HLA class I alpha1 domain induced the production of ceramide which was blocked by addition of the phosphatidylcholine-dependent phospholipase C inhibitor, D609. Furthermore, HLA class I-mediated apoptosis involved at least two different caspases, an interleukin-1 converting enzyme-like protease and another protease inhibited by the CPP32-like protease inhibitor Ac-DEVD-CHO. Despite similarity between Fas and HLA class I signaling pathways, we failed to demonstrate any physical association between these two molecules. We also report that the pan-caspase inhibitory peptide zVAD-fmk, but not Ac-DEVD-CHO and Ac-YVAD-CHO, inhibited decrease of mitochondrial transmembrane potential and generation of ceramide induced by anti-HLA class I and anti-Fas monoclonal antibodies, whereas all three peptides efficiently inhibited apoptosis. Altogether these results suggest that signaling through Fas and HLA class I involve caspase(s), targeted by zVAD-fmk, which act upstream of ceramide generation and mitochondrial events, whereas interleukin-1 converting enzyme-like and CPP32-like proteases act downstream of the mitochondria.